Hot or Not, Stock Market Edition: 08/28/2025

What’s hot and what’s not? We’ve got the story:

• Hot: Why MasTec (MTZ) deserves your undivided attention; Eli Lilly and Company (LLY) stresses to impress
• Not: Keurig Dr Pepper (KDP) shares take a tumble; despite recent good news, Boeing (BA) is still on the “not” list

P.S. For more stocks making moves, check out our new Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: If you’re looking for a lesser-known stock with some serious Growth potential (A rating), you need to give MasTec (NYSE: MTZ) your undivided attention. MasTec is an infrastructure company that specializes in energy and communication utilities, which are all the rage these days as energy demands continue to grow. MTZ lost 8.0% on August 1st after a mostly positive quarterly earnings report, but has since gained 14.0% since its post-earnings low, giving it some of the best momentum in the Engineering and Construction industry. Its A rating in Growth and B rating in Momentum, combined with the A rating the Engineering and Construction industry gets as a whole, makes MTZ a Strong Buy and gives it an A Zen Rating.

🥶 NOT: Shares of Keurig Dr Pepper Inc (NASDAQ: KDP) continued to tumble on Tuesday, losing another 6.9% to bring its total two-day loss to 17.6%. The impetus for the drop was KDP’s acquisition of JDE Peet’s, the owner of Peet’s coffee. The news came out of left field and sent markets reeling to figure out what impact the acquisition would have on Keurig Dr Pepper’s financials. We’re as surprised as everyone else about the deal, but we’re not writing off KDP entirely. The company’s Safety rating is still an A, reflecting the low volatility and high stability it had before Monday’s bombshell announcement. For now, we give KDP a C Zen Rating and a Hold recommendation.

🔥 HOT: Eli Lilly and Company (NYSE: LLY) impressed the world yet again on Tuesday, revealing that the latest trials of its experimental weight-loss drug, orforglipron, led to 10.5% weight loss in patients with Type 2 diabetes. Shares of LLY rose by 5.9% by the closing bell, continuing the momentum that started with the company’s last earnings report. LLY had a strong start to the year, followed by several months of choppy downtrend, so we’re remaining cautious for now. With B ratings in Value, Growth, Sentiment, and Financials, we feel comfortable giving LLY a B Zen Rating and a Buy recommendation.

> Learn more about Value stocks here

🥶 NOT: Boeing (NYSE: BA) gained 3.1% on Tuesday after Korean Air announced that it had placed an order for 103 Boeing planes worth around $20 billion. While that’s certainly good news, we’re not rushing out to place our buy orders just yet. Our analysis gives BA a D rating in Value, suggesting that the stock is entering overbought territory. We also give BA a D rating in Financials due to the recent spate of order cancellations. On the flip side, the stock gets an A rating in Growth and B ratings in Momentum and Safety. We view BA as a somewhat risky play right now but recognize that there could be significant upside to be had for risk-tolerant investors, so we give BA a C Zen Rating and a Hold recommendation.

What to Do Next?

• 9 Special Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.